Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

BMS 777607

Known as: BMS-777607, BMS777607, MET Tyrosine Kinase Inhibitor BMS-777607 
An inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibitor BMS-777607 binds to c-Met protein, or… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Tyro3, Axl, and Mertk (TAM) represent a family of homologous tyrosine kinase receptors known for their functional role in… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2019
Review
2019
Ovarian cancers remain one of the most common causes of gynecologic cancer-related death in women worldwide. The standard… 
  • figure 1
  • figure 2
  • table 1
  • table 1
  • figure 3
2016
2016
Purpose Receptor tyrosine kinase AXL (RTK-AXL) is regarded as suitable target in glioma therapy. Here we evaluate the anti… 
2013
2013
The RON receptor tyrosine kinase is a therapeutic target for cancer treatment. Here, we report therapeutic effect and phenotypic… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
Tyrosine kinase inhibitor BMS-777067 is an inhibitor of RON/MET receptor tyrosine kinases currently under clinical trials. Here… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
BACKGROUND We evaluated the mutation status of c-Met in small cell lung cancer (SCLC) and neuroendocrine tumors (NET), for which… 
Highly Cited
2010
Highly Cited
2010
Most prostate cancer–related deaths are due to advanced disease with patients with metastatic prostate cancer having a 5-year… 
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Highly Cited
2009
Highly Cited
2009
Substituted N-(4-(2-aminopyridin-4-yloxy)-3-fluoro-phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamides were… 
  • table 1
  • figure 3
  • figure 1
  • table 3
  • table 2